Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

ding the most common HCV genotype in the US and Europe, GT1.  

At the annual meeting of the American Association for the Study of Liver Diseases (AASLD), Professor Edward Gane of New Zealand presented results from ELECTRON demonstrating viral cure (sustained viral response, SVR) in 40 of 40 (100%) patients with HCV GT2 or GT3.  ELECTRON was designed to determine the minimum duration of interferon required to achieve SVR in combination with the nucleotide analog PSI-7977 and RBV.  All 40 subjects were treated with PSI-7977/RBV, but were randomized to receive one of four "interferon sparing" or interferon-free regimens: 4, 8, or 12 weekly interferon injections, or no interferon. The early antiviral responses were consistent across all four experimental treatment groups with all 40 subjects achieving "undetectable" HCV RNA by week 4.  Importantly, there were no treatment failures or discontinuations due to safety or viral resistance during the 12 weeks of therapy, problems that have limited the effectiveness of other direct-acting antivirals in development for HCV.  

Data from PROTON, the Phase 2 dose-ranging trial for PSI-7977, were presented at AASLD by Dr. Eric Lawitz.  Initial 12-week safety and on-treatment response rates had been presented in early 2011, with 98% of subjects achieving HCV below limit of detection (<LOD), and no safety or tolerability issues in either cohort receiving PSI-7977 at 200 mg or 400 mg QD with Peg-IFN/RBV for 12 weeks.  During the Peg-IFN/RBV dosing from week 13 to 24, three subjects in the 200 mg cohort experienced viral breakthrough and one additional subject experienced relapse within 4 weeks of completing the treatment, for a combined 88% SVR12 for the lower-dose of PSI-7977.  In contrast, no viral breakthrough was observed in the PSI-7977 400 mg QD cohort, and only one relapse, for an intent to treat (ITT) SVR12 of 91% (43 of 47). Of the 44 subjects who received at least 8 we
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
(Date:3/25/2015)... is one of the most attractive in the emerging ... a growing economy and increasing government investment in healthcare, ... Russian market is set to grow at twice the ... around 10-15% annually reaching an approximate market value of ... Green Cross provides total healthcare solutions that ...
(Date:3/25/2015)... 25, 2015 The surging prevalence ... have fuelled social media growth, with over 50% ... in social networking. Insurance companies are making use ... clients and promote a diversity of their services ... increasingly exploiting social networking services as part of ...
(Date:3/25/2015)... Mass. and REYKJAVIK, Iceland , ... capabilities for using the genome to create better medicine, today ... the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around the most ... a team of deCODE scientists led by Kari Stefansson ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2
... approval, revolutionary CiTop™ product-line is now available in Israel. Ovalum Ltd., ... clearance to market of its unique CiTop™ product-line in Israel. ... ... Ltd., a privately held Israeli medical device company, has announced today ...
... WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and medical ... and the United,States, today announced that it was awarded ... its CEO Dr. Ge Li was named one of ... the 8th China,Enterprise Innovation Forum held in Beijing last ...
... 2 Health Systems Implement Diagnosis Decision Support & Knowledge ... ... July 10 Isabel Healthcare, a leading,provider of diagnosis decision ... Midelfort-Mayo Health System, Eau Claire,WI and Children,s Hospitals and Clinics ...
Cached Biology Technology:Ovalum Ltd. Received Clearance to Market the CiTop&#8482; Product-Line in Israel 2WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises 2Isabel Healthcare Adds Hospitals in Wisconsin & Minnesota 2
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... study of its kind, researchers have used tools of paleontology ... chemicals. They have shown that during the evolution of these ... rarer, harder to synthesise forms, giving pointers that will help ... the fossil record has allowed the study of the evolution ...
... of the immune systemcapable of targeting proteins associated with ... biomedical research, the development of diagnostic tests and for ... however, has often been a difficult, costly and laborious ... the Biodesign Institute at Arizona State University have developed ...
... DNA construction, also known as DNA cloning or recombinant DNA ... one of the principal tools of modern biotechnology, used for ... and the development of advanced biofuels. A number of software ... Hillson, a biochemist at the U.S. Department of Energy (DOE),s ...
Cached Biology News:Nature reaches for the high-hanging fruit 2Improved method for capturing proteins holds promise for biomedical research 2Improved method for capturing proteins holds promise for biomedical research 3DNA construction software saves time, resources and money 2DNA construction software saves time, resources and money 3DNA construction software saves time, resources and money 4
... Lyophilized. Lyophilized from 2 mM sodium ... human liver. Cathepsin D is a major ... as a 52 kDa proenzyme. Overexpression of ... associated with higher risk of relapse and ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
... 10X Automation Buffer is a concentrated formulation ... autostainers employing capillary action technology, as well ... in collaboration with David Brigati M.D., Department ... OK. This buffer is recommended for all ...
... users requiring mass detection but not ... TOF Mass spectrometer is ideally suited ... for high performance mass analysis. ... analysis, protein detection, micro-satellite DNA characterization ...
Biology Products: